Related Experiment Video
Updated: Apr 30, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
70.1K
Efficacy of voglibose in type 2 diabetes
1Kawasaki Medical School, Department of Internal Medicine , 577 Matsushima, Kurashiki City, Okayama 701-0192 , Japan kka@med.kawasaki-m.ac.jp.
Expert Opinion on Pharmacotherapy
|May 7, 2014
Summary
Voglibose effectively manages postprandial hyperglycemia, a key target for preventing type 2 diabetes (T2DM) and reducing cardiovascular risk. It shows promise in preventing T2DM progression from impaired glucose tolerance (IGT).
Area of Science:
- Endocrinology
- Pharmacology
- Preventive Medicine
Background:
- Type 2 diabetes mellitus (T2DM) and prediabetes (impaired glucose tolerance, IGT) are global health crises.
- Postprandial hyperglycemia, even with controlled HbA1c, strongly correlates with cardiovascular risk.
- Targeting postprandial hyperglycemia is crucial for T2DM management and prevention.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of voglibose.
- To assess voglibose's role in preventing T2DM in individuals with IGT.
- To evaluate voglibose as add-on or combination therapy for T2DM.
Main Methods:
- Literature review of voglibose's properties and clinical applications.
- Focus on studies investigating T2DM prevention in IGT.
- Analysis of voglibose's use in combination with other oral antidiabetic agents.
Main Results:
- Voglibose is an effective α-glucosidase inhibitor for managing postprandial hyperglycemia.
- Evidence supports voglibose's efficacy in preventing T2DM progression from IGT.
- Voglibose demonstrates utility as an adjunct therapy in T2DM management.
Conclusions:
- Postprandial hyperglycemia is a critical therapeutic target, especially given its link to cardiovascular risk below the diabetic threshold.
- Preventing IGT progression to T2DM offers significant individual and societal benefits.
- Voglibose is a valuable therapeutic option, notably approved in Japan for T2DM prevention.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
17
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:22Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:26Type II Diabetes I: Introduction
17
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17